Michael Eskew - Eli Lilly Independent Director

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;padding-top: 25px;;'>EL</div>
LLY -- USA Stock  

Report: 30th of July 2020  

  Director
Mr. Michael L. Eskew is an Independent Director of the Company
Age: 69  Director Since 2008      
317 276-2000  www.lilly.com
Eskew has CEO experience with UPS, where he established a record of success in managing complex worldwide operations, strategic planning, and building a strong consumerbrand focus. He is an audit committee financial expert, based on his CEO experience and his service on other U.S. company audit committees. He has extensive corporate governance experience through his service on the boards of other companies.

Michael Eskew Latest Insider Activity

Eli Lilly Management Efficiency

Eli Lilly And has Return on Asset of 10.25 % which means that on every $100 spent on asset it made $10.25 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 192.05 %, implying that it generated $192.05 on every 100 dollars invested. Eli Lilly management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Eli Lilly Return on Average Assets are fairly stable at the moment as compared to the past year. Eli Lilly reported Return on Average Assets of 0.22 in 2019. Return on Average Equity is likely to grow to 3.19 in 2020, whereas Return on Investment is likely to drop 25.98 in 2020. Eli Lilly Total Assets are fairly stable at the moment as compared to the past year. Eli Lilly reported Total Assets of 39.29 Billion in 2019. Current Assets is likely to grow to about 15.7 B in 2020, whereas Goodwill and Intangible Assets are likely to drop slightly above 8.9 B in 2020. Eli Lilly Current Liabilities is fairly stable at the moment as compared to the past year. Eli Lilly reported Current Liabilities of 11.78 Billion in 2019. Tax Liabilities is likely to grow to about 6.4 B in 2020, whereas Total Liabilities is likely to drop slightly above 33.1 B in 2020.
The company has 17.63 B in debt with debt to equity (D/E) ratio of 5.52, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Eli Lilly And has a current ratio of 1.09, demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Robert BertoliniBristol Myers Squibb
2017
Etienne DavignonGilead Sciences
N/A
Ronald WilliamsJohnson Johnson
2011
Mark McClellanJohnson Johnson
2013
Christine SeidmanMerck Company
2020
Kevin LoftonGilead Sciences
2009
Carina LazaroGrifols S A
2015
Phyllis YaleBristol Myers Squibb
2019
John MadiganGilead Sciences
2005
William PerezJohnson Johnson
2007
Nicholas MooreGilead Sciences
2004
Craig ThompsonMerck Company
2008
Per WoldOlsenGilead Sciences
2010
Lynn ElsenhansGlaxoSmithKline PLC
2012
Stacey CartwrightGlaxoSmithKline PLC
2011
Deborah DiSanzoAstrazeneca PLC
2017
Vindi BangaGlaxoSmithKline PLC
2017
Stephanie BurnsGlaxoSmithKline PLC
2007
John NoseworthyMerck Company
2017
Laurie GlimcherGlaxoSmithKline PLC
2017
Philip BroadleyAstrazeneca PLC
2017

Company Summary

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 33815 people.Eli Lilly And (LLY) is traded on BATS Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN 46285, United States and employs 33,815 people. Eli Lilly And was previously known as ELI LILLY Co and was traded on BATS Exchange under the symbol LLY. Eli Lilly is listed under Pharmaceutical Products category by Fama And French industry classification.

Eli Lilly And Leadership Team

Ellen Marram, Lead Independent Director
Kathi Seifert, Independent Director
Ralph Alvarez, Independent Director
Jamere Jackson, Independent Director
Joshua Smiley, Chief Financial Officer, Senior Vice President
Anat Hakim, Senior Vice President General Counsel
Fionnuala Walsh, Senior Vice President - Global Quality
Johna Norton, Senior Vice President - Global Quality
Juan Luciano, Lead Independent Director
J Fyrwald, Independent Director
Alfonso Zulueta, Senior Vice President and President - Emerging Markets business
Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health
John Lechleiter, Chairman, CEO and Pres
Anne White, Senior Vice President and Presidentident - Lilly Oncology
Karen Horn, Independent Director
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Darren Carroll, Senior Vice President - Corporate Business Development
Patrik Jonsson, Senior Vice President and President - Lilly Bio-Medicines
William Kaelin, Independent Director
Karen Walker, Independent Director
Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines
Barton Peterson, Senior Vice President - Corporate Affairs and Communications
Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee
Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
Raul Alvarez, Independent Director
Marschall Runge, Independent Director
Michael Harrington, Executive Vice President, General Counsel
David Hoover, Independent Director
Maria Crowe, President - Manufacturing Operations
Myles ONeill, Senior Vice President and President - Manufacturing Operations
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines
Daniel Skovronsky, Senior Vice President - Science and Technology, and President Lilly Research Laboratories
Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories
Carolyn Bertozzi, Independent Director
Erik Fyrwald, Independent Director
Aarti Shah, Senior Vice President - Chief Information and Digital Officer
Susan Mahony, Senior Vice President and President - Lilly Oncology
Jackson Tai, Independent Director
Michael Eskew, Independent Director
Katherine Baicker, Independent Director
Stephen Fry, Senior Vice President - Human Resources and Diversity
Michael Mason, Senior Vice President and President Lilly Diabetes
Franklyn Prendergast, Independent Director

Stock Performance Indicators

Current Sentiment - LLY

Eli Lilly And Investor Sentiment

Predominant part of Macroaxis users are now bullish on Eli Lilly And. What is your opinion about investing in Eli Lilly And? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Instant Ratings module to determine any equity ratings based on digital recommendations. macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page